Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.59 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.59 |
| ▸ | PTGFR | P43088 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206771 | 0.98 | LTB4R (0.56) | LTB4RLTB4R2PTGFRPPARAMAPT | |
| SCHEMBL3264881 | 0.93 | HPGD (0.57) | PTGFRLMNAMTNR1AMTNR1BHDAC1 | |
| SCHEMBL10836137 | 0.90 | MTNR1A (0.56) | LTB4RLTB4R2PTGFRLMNAMTNR1A | |
| SCHEMBL17315856 | 0.87 | MTNR1A (0.56) | PPARAMTNR1AMTNR1BHDAC1HDAC6 | |
| SCHEMBL362209 | 0.86 | LMNA (0.59) | LMNAMTNR1AMTNR1BHPGD | |
| SCHEMBL29590071 | 0.86 | LMNA (0.59) | LMNAMTNR1AMTNR1BHPGD | |
| SCHEMBL6112796 | 0.86 | PPARA (0.55) | LTB4RLTB4R2PPARAMAPTRXFP1 | |
| SCHEMBL9669777 | 0.85 | TOP1 (0.50) | PTGFRLMNAMTNR1AMTNR1BHPGD | |
| Hydrochloric Acid SCHEMBL7413528 | 0.85 | LMNA (0.57) | LMNAMTNR1AMTNR1BHPGD | |
| SCHEMBL7827662 | 0.84 | ALOX5 (0.68) | LTB4RLTB4R2PPARAMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2161997-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Boger, Dale L. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150492-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150492-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-12-11 | — | — | WO | disclosed |
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| EP-1309552-A4 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | UNIV QUEENSLAND (AU) | 2005-07-20 | — | — | EP | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
| EP-1309552-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002008189-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | LTB4R 59/4885LTB4R2 55/4885PTGFR 554/4885 |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FADS1, FAAH, SCD | LTB4R 3660/4885LTB4R2 3466/4885PTGFR 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.